LUMENS BIOS CO. LTD.

As of March 31, 2026, LUMENS BIOS CO. LTD. carries a market capitalization of 35.02B, placing it among publicly traded companies globally. Its enterprise value stands at -21.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, LUMENS BIOS CO. LTD. has 24.05M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.21, and the price-to-book ratio stands at 0.32.

As of March 31, 2026, LUMENS BIOS CO. LTD. maintains a current ratio of 3.75, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.97, indicating moderate leverage, while an interest coverage ratio of -5.25 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, LUMENS BIOS CO. LTD. posted a negative return on equity (ROE) of -4.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.04, reflecting losses generated across the asset base. The company generates approximately 1.72B in revenue per employee across its workforce of 96.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.17 indicates how many times LUMENS BIOS CO. LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, LUMENS BIOS CO. LTD. recorded an income tax benefit of -4.55M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -5.03B and -5.03B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, LUMENS BIOS CO. LTD.'s stock has declined approximately 25.14% over the past 52 weeks. The 50-day moving average sits at 1,525.28, while the 200-day moving average is 1,669.60.

Over the twelve months ended March 31, 2026, LUMENS BIOS CO. LTD. generated 165.87B in revenue and converted that into -5.03B in net income, yielding earnings per share of -209.03. EBITDA reached -1.17B, while operating income came in at -4.82B.

As of March 31, 2026, LUMENS BIOS CO. LTD. holds 57.99B in cash and equivalents against 1.06B in total debt, resulting in a net debt position of -57.88B. Total book value stands at 109.67B, with working capital of 87.81B providing operational flexibility.

LUMENS BIOS CO. LTD. produced 1.78B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.76B in capital expenditures, free cash flow totaled -980.57M - equivalent to -40.77 per share.

Over the twelve months ended March 31, 2026, LUMENS BIOS CO. LTD. posted a gross margin of 10.42, reflecting its pricing power and cost economics. The operating margin of -2.91 and net profit margin of -3.03 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -2.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 18.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to LUMENS BIOS CO. LTD. shareholders.

LUMENS BIOS CO. LTD.'s most recent stock split took place on October 13, 2026 with a 2:1 split ratio.

As of March 31, 2026, LUMENS BIOS CO. LTD. has an Altman Z-Score of 1.97, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.